DE69228556D1 - CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE - Google Patents

CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE

Info

Publication number
DE69228556D1
DE69228556D1 DE69228556T DE69228556T DE69228556D1 DE 69228556 D1 DE69228556 D1 DE 69228556D1 DE 69228556 T DE69228556 T DE 69228556T DE 69228556 T DE69228556 T DE 69228556T DE 69228556 D1 DE69228556 D1 DE 69228556D1
Authority
DE
Germany
Prior art keywords
multiple sclerosis
cdw52
specific antibodies
treating multiple
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228556T
Other languages
English (en)
Other versions
DE69228556T2 (de
Inventor
H Prof Waldmann
Geoffrey Dr Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of DE69228556D1 publication Critical patent/DE69228556D1/de
Application granted granted Critical
Publication of DE69228556T2 publication Critical patent/DE69228556T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69228556T 1991-12-04 1992-12-04 CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE Expired - Lifetime DE69228556T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919125768A GB9125768D0 (en) 1991-12-04 1991-12-04 Therapeutic method
PCT/GB1992/002252 WO1993010817A1 (en) 1991-12-04 1992-12-04 CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS

Publications (2)

Publication Number Publication Date
DE69228556D1 true DE69228556D1 (de) 1999-04-08
DE69228556T2 DE69228556T2 (de) 1999-07-08

Family

ID=10705671

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228556T Expired - Lifetime DE69228556T2 (de) 1991-12-04 1992-12-04 CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE

Country Status (18)

Country Link
US (2) US6120766A (de)
EP (1) EP0616537B1 (de)
JP (1) JP3383303B2 (de)
KR (1) KR100271333B1 (de)
AT (1) ATE177011T1 (de)
AU (1) AU3089692A (de)
CA (1) CA2124964C (de)
DE (1) DE69228556T2 (de)
DK (1) DK0616537T3 (de)
ES (1) ES2128363T3 (de)
GB (1) GB9125768D0 (de)
GR (1) GR3029683T3 (de)
HK (1) HK1011618A1 (de)
IL (1) IL103981A (de)
MX (1) MX9207032A (de)
MY (1) MY111961A (de)
WO (1) WO1993010817A1 (de)
ZA (1) ZA929446B (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
JP2005517025A (ja) * 2002-02-08 2005-06-09 エクサイト セラピーズ， インコーポレイテッド 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
EP1539929B1 (de) 2002-06-28 2013-04-10 Life Technologies Corporation Verfahren zur wiederherstellung des immunrepertoirs in patienten mit immunologischen defekten in verbindung mit autoimmunität sowie transplantation von organen oder hämatopoetischen stammzellen
MXPA05012080A (es) * 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
EP1694706B1 (de) 2003-11-01 2012-04-04 Merck Patent GmbH Modifizierter anti-cd52-antikörper
CA2649296A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP1854810A1 (de) 2006-05-09 2007-11-14 PanGenetics B.V. De-immunisierter und antagonister monoclonaler Antikörper gegen CD40, der aus der ch5D12 Antikörper abgeleitet ist
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
ES2917882T3 (es) * 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H
LT2130044T (lt) 2007-02-16 2017-02-10 Genzyme Corporation Skydliaukės sutrikimo rizikos nustatymo būdas
EP3456733A1 (de) * 2007-05-11 2019-03-20 Genzyme Corporation Verfahren zur herstellung eines sekretierten proteins
TWI614267B (zh) * 2009-05-13 2018-02-11 建新公司 抗人類ｃｄ５２免疫球蛋白
BRPI1013927A2 (pt) 2009-05-13 2016-04-05 Genzyme Corp métodos e composições para o tratamento de lúpus
PT3214091T (pt) 2010-12-09 2019-01-11 Univ Pennsylvania Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
WO2013019615A2 (en) 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
EP2756521A4 (de) 2011-09-16 2015-04-22 Univ Pennsylvania Rna-manipulierte t-zellen zur behandlung von krebs
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773651B1 (de) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolierte b7-h4-spezifische zusammensetzungen und anwendungsverfahren dafür
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CA2864688C (en) 2012-02-22 2023-09-05 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
CA2864489C (en) 2012-02-22 2023-08-08 The Trustees Of The University Of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
WO2014011988A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
EP3584256A1 (de) 2012-07-13 2019-12-25 The Trustees Of The University Of Pennsylvania Verfahren zur beurteilung der eignung von transduzierten t-zellen zur verabreichung
CN104427997B (zh) 2012-07-13 2020-12-11 宾夕法尼亚大学董事会 对cars的抗肿瘤活性的毒性管理
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
CN105518018B (zh) * 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP3083964B1 (de) 2013-12-19 2022-01-26 Novartis AG Menschliche chimäre mesothelin-antigenrezeptoren und verwendungen davon
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
KR102487608B1 (ko) 2014-04-07 2023-01-12 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
WO2015168613A2 (en) 2014-05-02 2015-11-05 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3660042B1 (de) 2014-07-31 2023-01-11 Novartis AG T-zellen mit teilmengenoptimierten chimären antigenrezeptoren
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3204777A1 (de) 2014-10-08 2017-08-16 Novartis AG Prädiktive biomarker für das therapeutische ansprechen auf chimäre antigenrezeptortherapie und verwendung davon
ES2910227T3 (es) 2014-10-31 2022-05-12 Univ Pennsylvania Composición y métodos para la estimulación y expansión de células T
EP4219725A3 (de) 2014-10-31 2023-08-30 The Trustees of the University of Pennsylvania Änderung der genexpression in modifizierten t-zellen und verwendungen davon
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
JP7170394B2 (ja) 2015-01-31 2022-11-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 治療用分子のｔ細胞送達のための組成物および方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3259284B1 (de) 2015-02-16 2020-04-01 The Trustees of the University of Pennsylvania Vollhumaner t-zellrezeptor spezifisch für das 369 377-epitop aus dem her2/neu (erbb2)-rezeptorprotein
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
EP3280795B1 (de) 2015-04-07 2021-03-24 Novartis AG Kombination von chimärer antigen rezeptor therapie und amino pyrimidin derivaten
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
WO2018126369A1 (en) 2017-01-05 2018-07-12 Shanghai Sidansai Biotechnology Co., Ltd Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
US11649435B2 (en) 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3340995A4 (de) 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania Verfahren und zusammensetzungen für zellen zur expression eines chimären intrazellulären signalmoleküls
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
EP3359650A4 (de) 2015-10-08 2019-03-20 Innovative Cellular Therapeutics Co., Ltd. Aktivierung und expansion von zellen
JP7118887B2 (ja) 2015-11-23 2022-08-16 ノバルティス アーゲー 最適化されたレンチウイルス移入ベクターおよびその使用
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
CN113082201A (zh) 2016-04-01 2021-07-09 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
RU2018140056A (ru) 2016-04-15 2020-05-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3485017A4 (de) 2016-07-18 2020-03-04 Helix Biopharma Corp. Gegen das mit dem karzinoembryonischen antigen in verbindung stehende zelladhäsionsmolekül 6 gerichtete car-immunzellen zur behandlung von krebs
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
EP3523331A1 (de) 2016-10-07 2019-08-14 Novartis AG Chimäre antigenrezeptoren zur behandlung von krebs
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3558348A1 (de) 2016-12-21 2019-10-30 TCR2 Therapeutics Inc. Manipulierte t-zellen zur behandlung von krebs
EP3589662A4 (de) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Induzierbares monovalentes antigenbindendes protein
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3621648A4 (de) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. Auf trispezifische proteine abzielendes msln und verfahren zur verwendung
EP3638295A1 (de) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
AU2018346719A1 (en) 2017-10-06 2020-04-23 Oslo Universitetssykehus Hf Chimeric antigen receptors
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
EP3694871A4 (de) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B-zellreifungs-antigenbindende proteine
JP2021502979A (ja) 2017-11-15 2021-02-04 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
EP3684399A1 (de) 2017-12-29 2020-07-29 Cellectis Verfahren zur verbesserung der produktion von car-t-zellen
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (de) 2018-02-13 2020-12-23 Novartis AG Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
CA3101028A1 (en) 2018-06-05 2019-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
WO2020036875A1 (en) 2018-08-13 2020-02-20 Rootpath Genomics, Inc. High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
CN113039209A (zh) 2018-08-30 2021-06-25 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
EP3856779A1 (de) 2018-09-28 2021-08-04 Novartis AG Chimäre cd22-antigen-rezeptor(car)-therapien
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
JP7379654B2 (ja) 2019-03-15 2023-11-14 カーティザン セラピューティクス，インコーポレーテッド 抗ｂｃｍａキメラ抗原受容体
AU2020253491A1 (en) 2019-04-05 2021-10-28 Rootpath Genomics, Inc. Compositions and methods for T-cell receptor gene assembly
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3162892A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4106806A1 (de) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3-bindende proteine und verfahren zur verwendung
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag zbtb32 inhibitors and uses thereof
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
JP3383303B2 (ja) 2003-03-04
CA2124964C (en) 2005-03-15
JPH07504888A (ja) 1995-06-01
HK1011618A1 (en) 1999-07-16
KR100271333B1 (ko) 2000-11-01
AU3089692A (en) 1993-06-28
GR3029683T3 (en) 1999-06-30
MX9207032A (es) 1993-07-01
DK0616537T3 (da) 1999-09-27
EP0616537B1 (de) 1999-03-03
GB9125768D0 (en) 1992-02-05
US20050118172A1 (en) 2005-06-02
IL103981A0 (en) 1993-05-13
ES2128363T3 (es) 1999-05-16
DE69228556T2 (de) 1999-07-08
WO1993010817A1 (en) 1993-06-10
US6120766A (en) 2000-09-19
ATE177011T1 (de) 1999-03-15
IL103981A (en) 1997-07-13
ZA929446B (en) 1993-08-19
EP0616537A1 (de) 1994-09-28
MY111961A (en) 2001-03-31
CA2124964A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
DE69228556D1 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69232539T2 (de) Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
IL97909A (en) Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ATE174515T1 (de) Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen
ATE126704T1 (de) Bcrf1-antagonisten zur behandlung von epstein- barr-virus-infektionen.
DE68924963T2 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition